Women of color constitute the majority of new HIV new diagnoses among all women in the US and dependent areas in 2018. Nearly a decade after the approval of the first oral biomedical HIV prevention strategy, cisgender women’s options for prevention remain limited and participation in prevention research trials face challenges. As a matter of health equity and justice, biomedical HIV prevention research must meaningfully include all women. This critical discussion will address what the field can do to close these continued gaps.
Host: Ken Williams, Ken Like Barbie